Pharmacogenomic variability and anaesthesia

British Journal of Anaesthesia

Volumn 103, Issue 1, 2009, Pages 14-25

  Searle, R ^a   Hopkins, P M ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anaesthetics gases, nitrous oxide; Anaesthetics i.v.; Anaesthetics volatile; Genetic factors; Malignant hyperthermia; Pharmacodynamics; Pharmacology agonists

Indexed keywords

ANESTHETIC AGENT; ANESTHETIC GAS; BETA ARRESTIN; CATECHOL METHYLTRANSFERASE; CODEINE; DIHYDROCODEINE; DIHYDROMORPHINE; DNA; DOUBLE STRANDED DNA; HYDROCODONE; INHALATION ANESTHETIC AGENT; MELANOCORTIN 1 RECEPTOR; MESSENGER RNA; MORPHINE; MU OPIATE RECEPTOR; NITROUS OXIDE; OPIATE; OXYCODONE; OXYMORPHONE; TRAMADOL; INTRAVENOUS ANESTHETIC AGENT; NARCOTIC ANALGESIC AGENT;

AGRANULOCYTOSIS; CHROMOSOME ANALYSIS; CHRONIC PAIN; DRUG ABSORPTION; DRUG ELIMINATION; DRUG METABOLISM; GENE LOCUS; GENERAL ANESTHESIA; GENETIC TRAIT; GENETIC VARIABILITY; HEREDITY; HUMAN; MALIGNANT HYPERTHERMIA; MEDICAL RESEARCH; MEGALOBLASTIC ANEMIA; NEUROPATHY; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; TUMOR CELL; UNSPECIFIED SIDE EFFECT; ANESTHESIA; METHODOLOGY; PHARMACOGENETICS;

ANALGESICS, OPIOID; ANESTHESIA; ANESTHETICS, INHALATION; ANESTHETICS, INTRAVENOUS; GENETIC VARIATION; HUMANS; PHARMACOGENETICS;

EID: 67650710929     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep130     Document Type: Review

References (89)

1. Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology 2003; 98: 1415-21
2. Berthele A, Platzer S, Jochim B, et al. COMT Val(108/158) Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and pre-proenkephalin mRNA expression. Neuroimage 2005; 28: 185-93
3. Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679-85
4. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999; 286: 2495-8
5. Bond C, LaForge KS, Tian MT, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608-13
6. Cascio M, Xing Y, Gong D, et al. Mouse chromosome 7 harbors a quantitative trait locus for isoflurane minimum alveolar concentration. Anesth Analg 2007; 105: 381-5
7. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988; 2: 914-5
8. Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolizers. Br J Clin Pharmacol 1991; 31: 381-90
9. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphlism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105: 334-7
10. Chou WY, Yang LC, Lu HF, et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006; 50: 787-92
11. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006; 80: 682-90
12. Cordell HJ, Clayton DG. Genetic association studies. Lancet 2005; 366: 1121-31
13. Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006; 79: 316-24
14. Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth 1962; 34: 395-6
15. Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41: 23-6
16. Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996; 41: 7-12
17. Eap CB, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001; 21: 229-34
18. Eckhardt K, Li SX, Ammon S, Schanzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27-33
19. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 2006; 102: 146-50
20. Epstein RM, Rackow H, Salanitre E, Wolf GL. Influence of the concentration effect on the uptake of anesthetic mixtures: the second gas effect. Anesthesiology 1964; 25: 364-71
21. Ezri T, Sessler D, Weisenberg M, et al. Association of ethnicity with the minimum alveolar concentration of sevoflurane. Anesthesiology 2007; 107: 9-14
22. Hayashida M, Nagashima M, Satoh Y, et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008; 9: 1605-16
23. Hogan K. Pharmacogenetics of nitrous oxide: standing at the crossroads. Anesthesiology 2008; 109: 5-6
24. Humphrey JA, Sedensky MM, Morgan PG. Understanding anesthesia: making genetic sense of the absence of senses. Hum Mol Genet 2002; 11: 1241-9
25. Ikeda K, Ide S, Han WH, Hayashida M, Uhl GR, Sora I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 2005; 26: 311-7
26. Iles DE, Lehmann-Horn F, Scherer SW, et al. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet 1994; 3: 969-75
27. Ingelman-Sundberg M. Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab Rev 1999; 31: 449-59
28. International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-61
29. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921
30. Iohom G, Ni Chonghaile M, O'Brien JK, Cunningham AJ, Fitzgerald DF, Shields DC. An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. Eur J Anaesthesiol 2007; 24: 912-9
31. Janicki PK, Schuler G, Francis D, et al. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 2006; 103: 1011-7
32. Kalow W. Pharmacogenetics and anesthesia. Anesthesiology 1964; 25: 377-87
33. Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Biochem Physiol 1957; 35: 1305-20
34. Kim H, Lee H, Rowan J, Brahim J, Dionne RA. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain 2006; 2: 9
35. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7: 257-65
36. Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A.> polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48: 1232-9
37. Lacassie HJ, Nazar C, Yonish B, Sandoval P, Muir HA, Mellado P. Reversible nitrous oxide myelopathy and a polymorphism in the gene encoding 5,10-methylenetetrahydrofolate reductase. Br J Anaesth 2006; 96: 222-5
38. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79: 461-79
39. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fenta-nyl analgesia requirements in laboring women. Pain2008; 139: 5-14
40. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2) - impli-cations for altered drug disposition and central nervous system drug entry. J Biol Chem 2005; 280: 9610-7
41. Levitt RC, Olckers A, Meyers S, et al. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 1992; 14: 562-6
42. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. Anesthesiology 2004; 101: 279-83
43. Lotsch J. Basic genetic statistics are necessary in studies of functional associations in anesthesiology. Anesthesiology 2007; 107: 168-9
44. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12: 3-9
45. Lotsch J, Skarke C, Schmidt H. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther 2006; 79: 35-48
46. Lotsch J, Skarke C, Wieting J. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006; 79: 72-89
47. Lovlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001; 11: 45-55
48. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of personalized medicine. AAPS Pharm Sci 2000; 2: E4
49. 2+ channels by heterologously expressed wild-type and mutant human mu-opioid receptors (hMORs) containing the A118G single-nucleotide polymorphism. J Neurophysiol 2007; 97: 1058-67
50. Meineke I, Freudenthaler S, Hofmann U, et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002; 54: 592-603
51. Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005; 42: 583-7
52. Mogil JS, Wilson SG, Chesler EJ, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 2003; 100: 4867-72
53. Monnier N, Krivosic-Horber R, Payen JF, et al. Presence of two different genetic traits in malignant hyperthermia families: implications for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97: 1067-74
54. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60: 1316-25
55. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta(2)- and beta(3)-adrenergic receptors. Pain 2007; 128: 199-208
56. Nagele P, Zeugswetter B, Wiener C, et al. Influence of methy-lenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology 2008; 109: 36-43
57. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006; 16: 625-36
58. Persson K, Sjostrom S, Sigurdardottir I, Molnar V, Hammarlundudenaes M, Rane A. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolizers and one poor metabolizer of dextromethorphan. Br J Clin Pharmacol 1995; 39: 182-6
59. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoal-gesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636-44
60. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metab-olizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-95
61. Poulsen L, Riishede L, Brosen K, Clemensen S, Sindrup SH. Codeine in post-operative pain - study of the influence of spar-teine phenotype and serum concentrations of morphine and morphine-6-glucuronide. Eur J Clin Pharmacol 1998; 54: 451-4
62. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005; 116: 73-8
63. Reyes-Gibb CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007; 130: 25-30
64. Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11: 342-8
65. Robinson RL, Carpenter D, Shaw M-A, Halsall PJ, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27: 977-89
66. Robinson RL, Curran JL, Ellis FR, et al. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet 2000; 64: 307-20
67. Robinson RL, Hopkins PM, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet 2003; 112: 217-8
68. Robinson R, Monnier N, Wolz W, et al. A genome-wide search for susceptibility loci in two European malignant hyperthermia pedigrees. Hum Mol Genet 1997; 6: 953-61
69. Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008; 9: 905-33
70. Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005; 5: 324-36
71. Samer C, Daali Y, Rebsamen M, Chiappe A, Desmeules J, Dayer P. Determinant role of CYP2D6 and CYP3A4 pathways on the antinociceptive effects of oxycodone. Clin Pharmacol Ther 2005; 79: 57
72. Sato Y, Seo N, Kobayashi E. Genetic background differences between FVB and C57BL/6 mice affect hypnotic susceptibility to pentobarbital, ketamine and nitrous oxide, but not isoflurane. Acta Anaesthesiol Scand 2006; 50: 553-6
73. Selzer RR, Rosenblatt DS, Laxova R, Hogan K. Adverse effect of nitrous oxide in a child with 5,10-methylenetetrahydrofolate reductase deficiency. N Engl J Med 2003; 3: 45-50
74. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429-44
75. Sonner JM, Gong D, Eger EI, II. Naturally occurring variability in anesthetic potency among inbred mouse strains. Anesth Analg 2000; 91: 720-6
76. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-8
77. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantio-mers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007; 82: 41-7
78. Sweeney BP. Pharmacogenomics and anaesthesia: explaining the variability in response to opiates. Eur J Anaesthesiol 2007; 24: 209-12
79. Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nocicep-tion, and opiate responses. Proc Natl Acad Sci USA 1999; 96: 7752-5
80. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for the molecular detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-7
81. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51
82. Vree TB, Van Dongen RTM, Koopman-Kimenai PM. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract 2000; 54: 395-8
83. Wang GX, Zhang H, He FF, Fang XM. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62: 927-31
84. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78
85. Williams DG, Patel A, Howard RF. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 2002; 89: 839-45
86. Winnie AP, Collins VJ. The subclavian perivascular technique of brachial plexus anesthesia. Anesthesiology 1964; 25: 353-63
87. Yue QY, Svensson JO, Alm C, Sjoqvist F, Sawe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989; 28: 639-45
88. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedebergs Arch Pharmacol 2004; 369: 23-37
89. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val(158)met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299: 1240-3